Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31339978 | 0.86 | BTK (0.48) | TRPV1SORT1MCHR1LCK | |
| SCHEMBL31339990 | 0.85 | SORT1 (0.50) | TRPV1SORT1MCHR1LCKTEK | |
| SCHEMBL31339954 | 0.85 | VNN1 (0.45) | TRPV1SORT1MCHR1 | |
| SCHEMBL31340012 | 0.84 | KDM4E (0.46) | TRPV1SORT1LCK | |
| SCHEMBL31340005 | 0.83 | TRPV1 (0.46) | TRPV1HDAC3HDAC8HDAC6 | |
| SCHEMBL31339987 | 0.83 | TRPV1 (0.57) | TRPV1KDRTEK | |
| SCHEMBL31339981 | 0.82 | ALDH1A1 (0.43) | TRPV1SORT1MCHR1 | |
| SCHEMBL34462417 | 0.79 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL31340007 | 0.78 | PTGS1 (0.54) | TRPV1SORT1 | |
| SCHEMBL31339962 | 0.78 | LCK (0.59) | TRPV1LCKKDRJAK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | JILIN UNIVERSITY (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4725485-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | Jilin University (CN) | 2026-04-15 | — | — | EP | disclosed |
| CN-119285557-A | CD97 and GSDME interaction inhibitor with anti-tumor activity and application thereof | 吉林大学 | 2025-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124202-A1 | CD97 AND GSDME INTERACTION INHIBITOR HAVING ANTI-TUMOR ACTIVITY AND APPLICATION THEREOF | GZMB, CD74, GSDMD | TRPV1 1150/4885SORT1 4391/4885MCHR1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.